• Products
  • Insights
  • Practice Management
  • Resources
  • About Us

Domestic Equity fund

Hartford Healthcare Fund   

MORNINGSTAR RATING:
Overall, 4 stars, 3-Year, 3 stars, 5-Year, 3 stars, and 10-Year, 4 stars, rated against 158, 158, 146 and 113 products, respectively. Morningstar RatingTM is calculated for products with at least a 3-year history, based on a risk-adjusted return measure (excluding any applicable sale charges) and accounts for variations in a product's monthly performance. 5 stars are assigned to the top 10%; 4 stars to the next 22.5%, 3 stars to the next 35%, 2 stars to the next 22.5% and 1 star to the bottom 10%. ETFs and mutual funds are considered a single population. The Overall Rating is derived from a weighted average of the performance figures associated with its 3-, 5-, and 10-year (if applicable) Morningstar Rating metrics. For more information about these ratings, including their methodology, please go to global.morningstar.com/managerdisclosures . Ratings for other share classes may vary and are subject to change monthly. Past performance is no guarantee of future performance.
©2024 Morningstar, Inc. All rights reserved. The information contained herein: (1) is proprietary to Morningstar and/ or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.
overall (as of 9/30/2024)
158 PRODUCTS
Health Category
Based on Risk-Adjusted Returns
MORNINGSTAR RATING:
Overall, 4 stars, 3-Year, 3 stars, 5-Year, 3 stars, and 10-Year, 4 stars, rated against 158, 158, 146 and 113 products, respectively. Morningstar RatingTM is calculated for products with at least a 3-year history, based on a risk-adjusted return measure (excluding any applicable sale charges) and accounts for variations in a product's monthly performance. 5 stars are assigned to the top 10%; 4 stars to the next 22.5%, 3 stars to the next 35%, 2 stars to the next 22.5% and 1 star to the bottom 10%. ETFs and mutual funds are considered a single population. The Overall Rating is derived from a weighted average of the performance figures associated with its 3-, 5-, and 10-year (if applicable) Morningstar Rating metrics. For more information about these ratings, including their methodology, please go to global.morningstar.com/managerdisclosures . Ratings for other share classes may vary and are subject to change monthly. Past performance is no guarantee of future performance.
©2024 Morningstar, Inc. All rights reserved. The information contained herein: (1) is proprietary to Morningstar and/ or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.
overall (as of 9/30/2024)
158 PRODUCTS
Health Category
Based on Risk-Adjusted Returns

Domestic Equity fund

Hartford Healthcare Fund   
Share Class - I (HGHIX)

Objective

Seeks long-term capital appreciation.

Overview

A stock fund that invests exclusively in health care, a sector that is experiencing innovations and breakthroughs across multiple subsectors.

Portfolio Management
Senior Managing Director
Global Industry Analyst
4
YRS
MANAGING THIS FUND
17
YRS
AT WELLINGTON MANAGEMENT
19
YRS
EXPERIENCE IN THIS INDUSTRY
Managing Director
Global Industry Analyst
3
YRS
MANAGING THIS FUND
9
YRS
AT WELLINGTON MANAGEMENT
17
YRS
EXPERIENCE IN THIS INDUSTRY
Managing Director
Global Industry Analyst
2
YRS
MANAGING THIS FUND
11
YRS
AT WELLINGTON MANAGEMENT
25
YRS
EXPERIENCE IN THIS INDUSTRY

The portfolio managers are supported by the full resources of Wellington.

Performance

PERFORMANCE %
 
CUMULATIVE %
(as of 10/31/2024)
AVERAGE ANNUAL TOTAL RETURNS %
(as of 10/31/2024)
YTD 1YR 3YR 5YR 10YR SI
Hartford Healthcare I 7.17 20.78 -0.05 8.54 8.67 10.86
Benchmark 8.85 20.04 4.12 10.81 10.06 ---
 
CUMULATIVE %
(as of 9/30/2024)
AVERAGE ANNUAL TOTAL RETURNS %
(as of 9/30/2024)
YTD 1YR 3YR 5YR 10YR SI
Hartford Healthcare I 13.46 23.09 2.80 11.11 10.01 11.15
Benchmark 14.01 21.46 7.44 12.91 11.15 ---

Performance data quoted represents past performance and does not guarantee future results. The investment return and principal value of an investment will fluctuate so that an investor's shares, when redeemed, may be worth more or less than their original cost. Current performance may be lower or higher than the performance data quoted.

SI = Since Inception. Fund Inception: 05/01/2000

Share Class Inception: 8/31/06.
Class I-share performance prior to its inception date reflects Class A-share performance (excluding sales charges) and operating expenses. SI performance is calculated from 5/1/00.

Hartford Healthcare Fund I Share Morningstar Ratings
Morningstar Medalist RatingTM
9/26/2024
overall
(as of 9/30/2024)
Overall, 4 stars, 3-Year, 3 stars, 5-Year, 3 stars, and 10-Year, 4 stars, rated against 158, 158, 146 and 113 products, respectively. Morningstar RatingTM is calculated for products with at least a 3-year history, based on a risk-adjusted return measure (excluding any applicable sale charges) and accounts for variations in a product's monthly performance. 5 stars are assigned to the top 10%; 4 stars to the next 22.5%, 3 stars to the next 35%, 2 stars to the next 22.5% and 1 star to the bottom 10%. ETFs and mutual funds are considered a single population. The Overall Rating is derived from a weighted average of the performance figures associated with its 3-, 5-, and 10-year (if applicable) Morningstar Rating metrics. For more information about these ratings, including their methodology, please go to global.morningstar.com/managerdisclosures . Ratings for other share classes may vary and are subject to change monthly. Past performance is no guarantee of future performance.
©2024 Morningstar, Inc. All rights reserved. The information contained herein: (1) is proprietary to Morningstar and/ or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.

158 PRODUCTS
|
Health Category
Based on Risk-Adjusted Returns
3 YEAR
(as of 9/30/2024)
Overall, 4 stars, 3-Year, 3 stars, 5-Year, 3 stars, and 10-Year, 4 stars, rated against 158, 158, 146 and 113 products, respectively. Morningstar RatingTM is calculated for products with at least a 3-year history, based on a risk-adjusted return measure (excluding any applicable sale charges) and accounts for variations in a product's monthly performance. 5 stars are assigned to the top 10%; 4 stars to the next 22.5%, 3 stars to the next 35%, 2 stars to the next 22.5% and 1 star to the bottom 10%. ETFs and mutual funds are considered a single population. The Overall Rating is derived from a weighted average of the performance figures associated with its 3-, 5-, and 10-year (if applicable) Morningstar Rating metrics. For more information about these ratings, including their methodology, please go to global.morningstar.com/managerdisclosures . Ratings for other share classes may vary and are subject to change monthly. Past performance is no guarantee of future performance.
©2024 Morningstar, Inc. All rights reserved. The information contained herein: (1) is proprietary to Morningstar and/ or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.

158 PRODUCTS
|
Health Category
Based on Risk-Adjusted Returns
5 YEAR
(as of 9/30/2024)
Overall, 4 stars, 3-Year, 3 stars, 5-Year, 3 stars, and 10-Year, 4 stars, rated against 158, 158, 146 and 113 products, respectively. Morningstar RatingTM is calculated for products with at least a 3-year history, based on a risk-adjusted return measure (excluding any applicable sale charges) and accounts for variations in a product's monthly performance. 5 stars are assigned to the top 10%; 4 stars to the next 22.5%, 3 stars to the next 35%, 2 stars to the next 22.5% and 1 star to the bottom 10%. ETFs and mutual funds are considered a single population. The Overall Rating is derived from a weighted average of the performance figures associated with its 3-, 5-, and 10-year (if applicable) Morningstar Rating metrics. For more information about these ratings, including their methodology, please go to global.morningstar.com/managerdisclosures . Ratings for other share classes may vary and are subject to change monthly. Past performance is no guarantee of future performance.
©2024 Morningstar, Inc. All rights reserved. The information contained herein: (1) is proprietary to Morningstar and/ or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.

146 PRODUCTS
|
Health Category
Based on Risk-Adjusted Returns
10 YEAR
(as of 9/30/2024)
Overall, 4 stars, 3-Year, 3 stars, 5-Year, 3 stars, and 10-Year, 4 stars, rated against 158, 158, 146 and 113 products, respectively. Morningstar RatingTM is calculated for products with at least a 3-year history, based on a risk-adjusted return measure (excluding any applicable sale charges) and accounts for variations in a product's monthly performance. 5 stars are assigned to the top 10%; 4 stars to the next 22.5%, 3 stars to the next 35%, 2 stars to the next 22.5% and 1 star to the bottom 10%. ETFs and mutual funds are considered a single population. The Overall Rating is derived from a weighted average of the performance figures associated with its 3-, 5-, and 10-year (if applicable) Morningstar Rating metrics. For more information about these ratings, including their methodology, please go to global.morningstar.com/managerdisclosures . Ratings for other share classes may vary and are subject to change monthly. Past performance is no guarantee of future performance.
©2024 Morningstar, Inc. All rights reserved. The information contained herein: (1) is proprietary to Morningstar and/ or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.

113 PRODUCTS
|
Health Category
Based on Risk-Adjusted Returns

Characteristics

FUND ESSENTIALS
Inception Date 05/01/2000
Net Assets $1.1 billion
Total Operating Expenses 1.01%
Morningstar Category Health
Lipper Classification Health/Biotechnology Funds
CUSIP 416649887
Fund Number 1309
FUND STATS
# of Holdings
100
% in Equities
98
% in Foreign Equities
17
Beta (3 year)
1.00
R Squared (3 year)
0.91
Standard Deviation
15.32%
Turnover
32%
Active Share
49%
Holdings Characteristics
FUND S&P Composite 1500 Health Care Index
Price/Earnings
28.5x 18.1x
Price/Book
5.5x 5.2x
EPS Growth Rate
21.7% 16.6%
Asset Weighted Market Cap (billions)
$219.7 $268.4
Return on Equity
19.0% 33.1%
Median Market Cap (billions)
$11.1 $7.1
Regional Exposure (%)
North America 83
Developed EU & Middle East ex UK 8
Japan 4
United Kingdom 4
Emerging Markets 1
North America 85
Developed EU & Middle East ex UK 7
United Kingdom 4
Japan 4
Emerging Markets 1
Top Ten Holdings (%)
Eli Lilly & Co. 10.89
UnitedHealth Group, Inc. 8.91
Merck & Co., Inc. 4.31
Danaher Corp. 3.78
Intuitive Surgical, Inc. 3.58
Boston Scientific Corp. 3.44
Thermo Fisher Scientific, Inc. 3.02
Vertex Pharmaceuticals, Inc. 2.50
HCA Healthcare, Inc. 2.31
AstraZeneca PLC 1.88
Total Portfolio % 44.62
Market Cap Distribution (%)

Market Cap Header3

Less than $2 billion 3
$2 billion - $5 billion 7
$5 billion - $10 billion 9
Greater than $10 billion 81
Not Classified 0
RETURN CHARACTERISTICS
Alpha (5 Year)
-1.53
Down Capture (5 Year)
102.46
Information Ratio (5 Year)
-0.35
Sharpe Ratio (5 Year)
0.58
Up Capture (5 Year)
95.84
Subsector Exposure (%)
Biopharma Large Cap 36
Health Care Services 26
Medical Technology 24
Biopharma Mid Cap 11
Biopharma Small Cap 3
Biopharma Large Cap 37
Medical Technology 23
Health Care Services 23
Biopharma Mid Cap 13
Biopharma Small Cap 3
Based on sub-adviser's classification of health care subsectors, which includes combining biotechnology and pharmaceuticals in terms of capitalization: biopharma small-cap, biopharma mid-cap, and biopharma large-cap. Excludes cash. May not total to 100% due to rounding.
distributions and capital gains
Distribution Date Distribution NAV ordinary income short term capital gains long term capital gains total distribution
12/27/2023 40.04 $0.0000 $0.0000 $0.0000 $0.0000
12/11/2023 38.31 $0.0000 $0.0000 $0.0000 $0.0000
Past distributions are not indicative of future distributions.

Fund Literature


09/30/2024 - PDF (179 KB)
This client flyer summarizes the Fund's investment approach, portfolio statistics, top holdings, and current performance
09/30/2024 - PDF (142 KB)
Current quarterly commentary from our sub-adviser, Wellington Management, which includes a performance review, attribution, statistics, and positioning and outlook for the Fund.
09/30/2024 - PDF (265 KB)
Current quarterly commentary from our sub-adviser, Wellington Management, which includes a performance review, attribution, statistics, and positioning and outlook for the Fund.
PDF (157 KB)
A summary of a fund's full-length prospectus that provides key information potential investors should consider before making an investment decision.
09/30/2024 - PDF (301 KB)
This Pitchbook reviews the Fund's investment approach, investment team, investment process, and general portfolio parameters.
An unaudited financial report, which includes a fund's financial statements. These reports are intended for shareholders and others who have reviewed the fund's prospectus.
PDF (13 KB)
A legal document that discloses essential information about a fund, including investment objectives, risks, fees, expenses, fund manager background and other information.
An audited financial report, which includes a fund's financial statements. These reports are intended for shareholders and others who have reviewed the fund's prospectus.
PDF (13 KB)
A document that supplements the fund's prospectus with additional information about the fund including its operations and risks.
Important Risks: Investing involves risk, including the possible loss of principal. Security prices fluctuate in value depending on general market and economic conditions and the prospects of individual companies. • Risks of focusing investments on the healthcare related sector include regulatory and legal developments, changes in funding or subsidies, patent and intellectual property considerations, intense competitive pressures, rapid technological changes, long and costly process for obtaining product approval by government agencies, potential product obsolescence, rising cost of medical products and services, and price volatility risk. • Small- and mid-cap securities can have greater risks and volatility than large-cap securities. • Foreign investments may be more volatile and less liquid than U.S. investments and are subject to the risk of currency fluctuations and adverse political, economic and regulatory developments. These risks may be greater, and include additional risks, for investments in emerging markets.
3566488